Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial [0.03%]
toll-like受体7/8抑制剂enpatoran治疗皮肤狼疮或系统性红斑狼疮患者的疗效和安全性：多中心国际双盲安慰剂对照剂量探索二期试验A组的研究结果
Eric F Morand,Victoria P Werth,Joerg Wenzel et al.
Eric F Morand et al.
Background: Toll-like receptor (TLR)7 and TLR8 are nucleic-acid sensors involved in lupus pathogenesis. We aimed to investigate the efficacy and safety of enpatoran, an oral small-molecule TLR7/8 inhibitor, in participant...
Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study [0.03%]
德国一般人群中骶髂关节骨髓水肿的流行病学和决定因素：一项基于人群的横断面研究
Keno Bressem,Murat Torgutalp,Torsten Diekhoff et al.
Keno Bressem et al.
Background: MRI-detected bone marrow oedema in sacroiliac joints is central to diagnosing axial spondyloarthritis, influencing treatment decisions including anti-inflammatory therapy initiation. However, the prevalence of...
Anti-MDA5-associated rapidly progressive-ILD-the intersection of hyperinflammation and fibrosis [0.03%]
抗MDA5相关快速进展性间质性肺病——炎症与纤维化的交叉点
Puja Mehta,Deepthi Joy,Marium Naqvi et al.
Puja Mehta et al.
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study [0.03%]
Branebrutinib（BMS-986195），一种不可逆的布鲁顿酪氨酸激酶抑制剂，用于治疗类风湿关节炎疗效和安全性的2a期、随机、双盲、安慰剂对照研究
Mikkel Østergaard,Espen A Haavardsholm,Miroslawa Nowak et al.
Mikkel Østergaard et al.
Background: Branebrutinib, an oral, highly selective, and irreversible Bruton's tyrosine kinase inhibitor, is a potential candidate for rheumatoid arthritis treatment as Bruton's tyrosine kinase has a role in B-cell activ...
Secondary haemophagocytic syndrome induced by levamisole-associated vasculitis [0.03%]
由噻苯达唑相关的血管炎引起的继发性噬血细胞综合征
Luis Javier Cajas Santana,Jhon Mora,Valentina López et al.
Luis Javier Cajas Santana et al.
Dissemination of study results to participants in rheumatology research: a meta-research review [0.03%]
风湿病研究中向参与者传播研究成果的元研究综述
Elsa-Lynn Nassar,Georgia Pierson,Claire Adams et al.
Elsa-Lynn Nassar et al.
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study [0.03%]
生物学和靶向合成治疗对类风湿关节炎合并慢性肾脏病患者的疗效及持久性：一项多中心前瞻性队列研究
Sho Fukui,Hilde S Ørbo,Sara K Tedeschi et al.
Sho Fukui et al.
Background: Chronic kidney disease is a common comorbidity of rheumatoid arthritis. Because there has been scarce and conflicting evidence on the use of biological and targeted synthetic therapy in patients with rheumatoi...
The Lancet Rheumatology
The Lancet Rheumatology
Paula S Ramos,Melissa A Cunningham
Paula S Ramos